FMP
ImmunoGen, Inc.
IMGN
NASDAQ
Inactive Equity
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
31.24 USD
0.005 (0.01601%)
Historical Prices
From:
To:
About
ceo
Mr. Mark Joseph Enyedy
sector
Healthcare
industry
Biotechnology
website
https://www.immunogen.comexchange
NASDAQ
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeut...
CIK
0000855654
ISIN
US45253H1014
CUSIP
45253H101
Address
830 Winter Street
Phone
781 895 0600
Country
US
Employee
277
IPO Date
Nov 17, 1989
Financial Statement
Earnings
IMGN Financial Summary
CIK
0000855654
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45253H101
ISIN
US45253H1014
Country
US
Price
31.23
Beta
1.17
Volume Avg.
8.29M
Market Cap
8.73B
Shares
-
52-Week
3.61-31.25
DCF
-11.66
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-111.55
P/B
-
Website
https://www.immunogen.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IMGN News
Investopedia
Feb 12, 2024
AbbVie Cuts Its Guidance on ImmunoGen Deal
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
Market Watch
Feb 12, 2024
AbbVie's stock dips premarket after it lowers Q1 guidance to...
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The company said it now expects first-quarter per-share earnings to range from $2.26 to $2.30, down from prior guidance of $2.30 to $2.34, including a 4 cent per share dilutive impact from the Immunogen deal.
Zacks Investment Research
Feb 9, 2024
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This ...
Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
Zacks Investment Research
Feb 9, 2024
ImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the S...
ImmunoGen (IMGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
InvestorPlace
Feb 6, 2024
7 Russell 2000 Stocks to Buy for the Next Bull Run: February...
As 2023 wrapped up, Russell 2000 stocks, mirroring the dynamics of small-to-mid-cap companies, showed resilience, outperforming their initial stance. The iShares Russell 2000 ETF (NYSEARCA: IWM ), a key barometer for these stocks, boasts over $60 billion in assets and a robust daily trading volume surpassing 40 million, setting an impressive stage for these agile market players.
Zacks Investment Research
Jan 9, 2024
How ImmunoGen (IMGN) Stock Stands Out in a Strong Industry
ImmunoGen (IMGN) has seen solid earnings estimate revision activity over the past two month, and belongs to a strong industry as well.
Zacks Investment Research
Jan 4, 2024
All You Need to Know About ImmunoGen (IMGN) Rating Upgrade t...
ImmunoGen (IMGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks Investment Research
Jan 4, 2024
New Strong Buy Stocks for January 4th
IMGN, GTLB, FNWD, BL and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on January 4, 2024.
